TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Copyright/Patent/Trademark CPT

H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; S. 369, Preserve Access to Affordable Generics Act; and S. 1315, Drug Price Competition Act of 2009

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: U.S. Customs & Border Protection; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1260 (111th), S. 1315 (111th), H.R. 1706 (111th), S. 369 (111th), S. 610 (111th), S. 515 (111th)

Health Issues HCR

H.R. 5561/S.3504, Emergency Contraception Education Act (increased Office of Generic Drugs funding) .

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); U.S. Customs & Border Protection; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR)

Bills named: S. 3504 (111th), H.R. 5561 (111th)

Trade (domestic/foreign) TRD

Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals and "paired port" issue.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; U.S. Customs & Border Protection

Pharmacy PHA

H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; Proposals relating to the "doughnut hole" impact; and implementation of healthcare reform legislation.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR); U.S. Customs & Border Protection; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 767 (111th), H.R. 1859 (111th)